WALTHAM, Mass., Nov. 9, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Eric Bouvier, BG Medicine's President and CEO, will present at the Lazard Capital Markets 9th Annual Healthcare Conference on November 14 at 3:00 PM Eastern Time (ET) in New York City.
To access the live and subsequently archived webcast of the presentation, go to the "Investors" section of the Company's website at http://investor.bg-medicine.com/events.cfm. Replays will be available on the Company's website for 30 days after the initial presentation.
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the discovery, development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. The Company's first commercialized product, the BGM Galectin-3® test for use in patients with chronic heart failure, is available in the United States and Europe. BG Medicine is also developing the CardioSCORE™ test, a blood test designed to aid in the assessment of an individual's risk for near-term major cardiovascular events. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.
The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352